DE69809561T2 - Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod - Google Patents
Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltodInfo
- Publication number
- DE69809561T2 DE69809561T2 DE69809561T DE69809561T DE69809561T2 DE 69809561 T2 DE69809561 T2 DE 69809561T2 DE 69809561 T DE69809561 T DE 69809561T DE 69809561 T DE69809561 T DE 69809561T DE 69809561 T2 DE69809561 T2 DE 69809561T2
- Authority
- DE
- Germany
- Prior art keywords
- dna
- mcc
- phlei
- cells
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 238000000034 method Methods 0.000 title abstract description 41
- 230000004663 cell proliferation Effects 0.000 title description 5
- 230000030833 cell death Effects 0.000 title description 4
- 230000001105 regulatory effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 172
- 241000187481 Mycobacterium phlei Species 0.000 claims abstract description 134
- 210000002421 cell wall Anatomy 0.000 claims abstract description 36
- 230000000694 effects Effects 0.000 claims abstract description 34
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 229940055036 mycobacterium phlei Drugs 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 71
- 201000011510 cancer Diseases 0.000 claims description 63
- 210000001616 monocyte Anatomy 0.000 claims description 60
- 238000011282 treatment Methods 0.000 claims description 37
- 238000004519 manufacturing process Methods 0.000 claims description 29
- 230000035755 proliferation Effects 0.000 claims description 29
- 230000000638 stimulation Effects 0.000 claims description 28
- 239000003937 drug carrier Substances 0.000 claims description 27
- 102000013462 Interleukin-12 Human genes 0.000 claims description 24
- 108010065805 Interleukin-12 Proteins 0.000 claims description 24
- 210000002540 macrophage Anatomy 0.000 claims description 22
- 210000000987 immune system Anatomy 0.000 claims description 19
- 230000001093 anti-cancer Effects 0.000 claims description 18
- 230000006882 induction of apoptosis Effects 0.000 claims description 18
- 239000008365 aqueous carrier Substances 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 13
- 102000004889 Interleukin-6 Human genes 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 102000003952 Caspase 3 Human genes 0.000 claims description 12
- 108090000397 Caspase 3 Proteins 0.000 claims description 12
- 230000006698 induction Effects 0.000 claims description 11
- 102000003814 Interleukin-10 Human genes 0.000 claims description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims description 10
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 8
- 206010059866 Drug resistance Diseases 0.000 claims description 5
- 230000016412 positive regulation of cytokine production Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 9
- 230000001939 inductive effect Effects 0.000 abstract description 7
- 102000011727 Caspases Human genes 0.000 abstract description 5
- 108010076667 Caspases Proteins 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 description 219
- 102000053602 DNA Human genes 0.000 description 217
- 230000006907 apoptotic process Effects 0.000 description 49
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 47
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 47
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 40
- 230000019734 interleukin-12 production Effects 0.000 description 40
- 241001529936 Murinae Species 0.000 description 29
- 229940117681 interleukin-12 Drugs 0.000 description 22
- 239000000969 carrier Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 206010005003 Bladder cancer Diseases 0.000 description 17
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 17
- 229940094991 herring sperm dna Drugs 0.000 description 17
- 201000005112 urinary bladder cancer Diseases 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 239000000725 suspension Substances 0.000 description 15
- 238000013467 fragmentation Methods 0.000 description 14
- 238000006062 fragmentation reaction Methods 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 11
- 101150064015 FAS gene Proteins 0.000 description 11
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 11
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 229940100601 interleukin-6 Drugs 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 10
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 229940076144 interleukin-10 Drugs 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000000975 bioactive effect Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 8
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- -1 but not limited to Proteins 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000000527 sonication Methods 0.000 description 7
- 102000016911 Deoxyribonucleases Human genes 0.000 description 6
- 108010053770 Deoxyribonucleases Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 6
- 244000309466 calf Species 0.000 description 6
- 230000005907 cancer growth Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 206010057248 Cell death Diseases 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 5
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 5
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000011987 methylation Effects 0.000 description 5
- 238000007069 methylation reaction Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000186359 Mycobacterium Species 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940127084 other anti-cancer agent Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108020000946 Bacterial DNA Proteins 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 206010048723 Multiple-drug resistance Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000324 minimal toxicity Toxicity 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229940124101 Caspase 3 inhibitor Drugs 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- 241000187480 Mycobacterium smegmatis Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000007799 cork Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079920 digestives acid preparations Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 102000054896 human PML Human genes 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000009416 procancer activity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- OBSLLHNATPQFMJ-UHFFFAOYSA-N 2,4-Dimethylthiazole Chemical compound CC1=CSC(C)=N1 OBSLLHNATPQFMJ-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000033399 Anaphylactic responses Diseases 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- 108010063593 DNA modification methylase SssI Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000012480 LAL reagent Substances 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 241000187644 Mycobacterium vaccae Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000187678 Nocardia asteroides Species 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 241000187563 Rhodococcus ruber Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 201000007580 appendix carcinoma Diseases 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- MKWYFZFMAMBPQK-UHFFFAOYSA-J sodium feredetate Chemical compound [Na+].[Fe+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O MKWYFZFMAMBPQK-UHFFFAOYSA-J 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5477797P | 1997-08-05 | 1997-08-05 | |
| US7506798P | 1998-02-18 | 1998-02-18 | |
| US7511198P | 1998-02-18 | 1998-02-18 | |
| US8631798P | 1998-05-21 | 1998-05-21 | |
| PCT/CA1998/000744 WO1999007383A1 (en) | 1997-08-05 | 1998-08-05 | Composition and method for regulating cell proliferation and cell death |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69809561D1 DE69809561D1 (de) | 2003-01-02 |
| DE69809561T2 true DE69809561T2 (de) | 2003-09-25 |
Family
ID=27489673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69809561T Expired - Lifetime DE69809561T2 (de) | 1997-08-05 | 1998-08-05 | Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6326357B1 (enExample) |
| EP (1) | EP1003525B1 (enExample) |
| JP (2) | JP4335435B2 (enExample) |
| KR (1) | KR100533576B1 (enExample) |
| AT (1) | ATE227996T1 (enExample) |
| AU (1) | AU736450B2 (enExample) |
| BR (1) | BR9815602A (enExample) |
| CA (1) | CA2299548C (enExample) |
| DE (1) | DE69809561T2 (enExample) |
| DK (1) | DK1003525T3 (enExample) |
| ES (1) | ES2187047T3 (enExample) |
| HU (1) | HU227921B1 (enExample) |
| IL (3) | IL134371A0 (enExample) |
| NO (1) | NO322450B1 (enExample) |
| NZ (1) | NZ502674A (enExample) |
| PT (1) | PT1003525E (enExample) |
| WO (1) | WO1999007383A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2299548C (en) | 1997-08-05 | 2009-12-29 | Bioniche Inc. | Composition and method for regulating cell proliferation and cell death |
| PT1054680E (pt) * | 1998-02-18 | 2005-06-30 | Bioniche Life Sciences Inc | Tratamento do cancro da bexiga pela parede celular de mycobacterium phlei |
| US6809081B1 (en) | 1998-12-04 | 2004-10-26 | Bioniche Life Sciences, Inc. | Chemotherapeutic composition and method |
| PT1135164E (pt) * | 1998-12-04 | 2004-11-30 | Bioniche Life Sciences Inc | Metodo para o tratamento de inflamacao |
| PT1135161E (pt) * | 1998-12-04 | 2005-01-31 | Bioniche Life Sciences Inc | Composicao e metodo terapeutico |
| US6794368B1 (en) * | 1999-04-01 | 2004-09-21 | Bioniche Life Sciences Inc. | Composition and method for inducing apoptosis in prostate cancer cells |
| PT1165106E (pt) * | 1999-04-01 | 2005-10-31 | Bioniche Life Sciences Inc | Composicoes e metodo para induzir apoptose em celulas de cancro da prostata, por m-adn e mcc |
| JP2002541264A (ja) | 1999-04-08 | 2002-12-03 | ユーエイビー・リサーチ・ファウンデーション | 冨ｇオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法 |
| WO2001022979A1 (en) * | 1999-09-29 | 2001-04-05 | Bioniche Life Sciences Inc. | Method to disrupt mitochondrial function |
| ATE455851T1 (de) * | 1999-12-13 | 2010-02-15 | Bioniche Life Sciences Inc | Therapeutisch nützliche synthetische oligonukleotide |
| DK1250152T3 (da) | 1999-12-28 | 2013-08-26 | Bioniche Urology Ip Inc | Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer |
| US20030044352A1 (en) * | 2001-04-24 | 2003-03-06 | Phillips Nigel C. | Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls |
| US6673566B1 (en) | 2002-01-10 | 2004-01-06 | The United States Of America As Represented By The Secretary Of Agriculture | Diagnosis of pathogen infections through analysis of nitrite production by antigen stimulated leukocytes |
| JP2009544680A (ja) | 2006-07-25 | 2009-12-17 | リポクセン テクノロジーズ リミテッド | ポリサッカライドによるタンパク質のｎ末端誘導体化 |
| AR083443A1 (es) | 2010-10-13 | 2013-02-27 | Bioniche Life Sciences Inc | Una composicion que comprende arn bacteriano y paredes celulares bacterianas, metodo para elaborar dicha composicion y sus usos |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3172815A (en) | 1962-04-24 | 1965-03-09 | Warner Lambert Pharmaceutical | Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof |
| FR2160326B1 (enExample) | 1971-11-19 | 1975-02-07 | Anvar | |
| US4152423A (en) | 1971-11-19 | 1979-05-01 | Agence Nationale De Valorisation De La Recherche (Anvar) | Immunological agents |
| US4010257A (en) | 1973-02-23 | 1977-03-01 | Burroughs Wellcome Co. | Biological extracts |
| US3976544A (en) | 1973-06-19 | 1976-08-24 | The Agence Nationale De Valorisation De Le Recherche | Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction |
| FR2374042A1 (fr) | 1976-06-04 | 1978-07-13 | Merieux Inst | Nouveau medicament immunostimulant et son procede de preparation |
| JPS54140710A (en) | 1978-03-10 | 1979-11-01 | Mitsui Toatsu Chem Inc | Anti-tumor substance and its preparation |
| DE3011461C2 (de) | 1980-03-25 | 1986-10-30 | Dr. Madaus & Co, 5000 Köln | Verwendung von Propionibakterien |
| US4520019A (en) | 1982-04-29 | 1985-05-28 | Ribi Immunochem Research, Inc. | Stable composition and preparation thereof |
| US4579941A (en) | 1982-08-13 | 1986-04-01 | Mitsuitoatsu Chemicals, Inc. | Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent |
| US4663306A (en) | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
| GB8404280D0 (en) | 1984-02-17 | 1984-03-21 | Stanford J L | Biological preparations |
| US4744984A (en) | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| ATE179333T1 (de) | 1993-01-29 | 1999-05-15 | Vetrepharm Inc | Immunotherapeutische zubereitung |
| CA2299548C (en) | 1997-08-05 | 2009-12-29 | Bioniche Inc. | Composition and method for regulating cell proliferation and cell death |
-
1998
- 1998-08-05 CA CA002299548A patent/CA2299548C/en not_active Expired - Fee Related
- 1998-08-05 DK DK98938555T patent/DK1003525T3/da active
- 1998-08-05 NZ NZ502674A patent/NZ502674A/en not_active IP Right Cessation
- 1998-08-05 EP EP98938555A patent/EP1003525B1/en not_active Expired - Lifetime
- 1998-08-05 DE DE69809561T patent/DE69809561T2/de not_active Expired - Lifetime
- 1998-08-05 AU AU87236/98A patent/AU736450B2/en not_active Ceased
- 1998-08-05 PT PT98938555T patent/PT1003525E/pt unknown
- 1998-08-05 AT AT98938555T patent/ATE227996T1/de active
- 1998-08-05 US US09/129,312 patent/US6326357B1/en not_active Expired - Lifetime
- 1998-08-05 HU HU0003012A patent/HU227921B1/hu not_active IP Right Cessation
- 1998-08-05 BR BR9815602-0A patent/BR9815602A/pt not_active Application Discontinuation
- 1998-08-05 WO PCT/CA1998/000744 patent/WO1999007383A1/en not_active Ceased
- 1998-08-05 ES ES98938555T patent/ES2187047T3/es not_active Expired - Lifetime
- 1998-08-05 KR KR10-2000-7001237A patent/KR100533576B1/ko not_active Expired - Fee Related
- 1998-08-05 IL IL13437198A patent/IL134371A0/xx active IP Right Grant
- 1998-08-05 JP JP2000506973A patent/JP4335435B2/ja not_active Expired - Fee Related
- 1998-08-05 US US09/129,313 patent/US6329347B1/en not_active Expired - Lifetime
-
2000
- 2000-02-03 IL IL134371A patent/IL134371A/en not_active IP Right Cessation
- 2000-02-04 NO NO20000576A patent/NO322450B1/no not_active IP Right Cessation
-
2007
- 2007-01-24 IL IL180924A patent/IL180924A/en not_active IP Right Cessation
-
2008
- 2008-05-12 JP JP2008124958A patent/JP2008208140A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL134371A (en) | 2007-07-24 |
| KR20010022643A (ko) | 2001-03-26 |
| AU8723698A (en) | 1999-03-01 |
| EP1003525B1 (en) | 2002-11-20 |
| NZ502674A (en) | 2002-06-28 |
| NO20000576L (no) | 2000-04-04 |
| PT1003525E (pt) | 2003-03-31 |
| US6326357B1 (en) | 2001-12-04 |
| JP2001513504A (ja) | 2001-09-04 |
| IL180924A0 (en) | 2007-07-04 |
| CA2299548A1 (en) | 1999-02-18 |
| ATE227996T1 (de) | 2002-12-15 |
| ES2187047T3 (es) | 2003-05-16 |
| WO1999007383B1 (en) | 1999-03-25 |
| KR100533576B1 (ko) | 2005-12-05 |
| NO322450B1 (no) | 2006-10-09 |
| EP1003525A1 (en) | 2000-05-31 |
| AU736450B2 (en) | 2001-07-26 |
| DE69809561D1 (de) | 2003-01-02 |
| US6329347B1 (en) | 2001-12-11 |
| JP2008208140A (ja) | 2008-09-11 |
| CA2299548C (en) | 2009-12-29 |
| BR9815602A (pt) | 2001-12-11 |
| DK1003525T3 (da) | 2003-03-24 |
| IL134371A0 (en) | 2001-04-30 |
| NO20000576D0 (no) | 2000-02-04 |
| WO1999007383A1 (en) | 1999-02-18 |
| HU227921B1 (hu) | 2012-06-28 |
| HUP0003012A3 (en) | 2004-03-29 |
| IL180924A (en) | 2010-11-30 |
| HUP0003012A2 (hu) | 2000-12-28 |
| JP4335435B2 (ja) | 2009-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69809561T2 (de) | Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod | |
| DE60036950T2 (de) | Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort | |
| KR20140031168A (ko) | 세균 리보핵산 세포벽 조성물 및 이들의 제조 및 사용 방법 | |
| DE69829316T2 (de) | Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand | |
| DE60020352T2 (de) | Zusammensetzung und Methode zur Inuzierung von Apptosis in Prostatakrebszellen mittels M-DNA und MCC | |
| DE69920506T2 (de) | Chemotherapeutische zusammensetzung und verfahren | |
| US6809081B1 (en) | Chemotherapeutic composition and method | |
| MXPA00001272A (en) | Composition and method for regulating cell proliferation and cell death | |
| EP1399168B1 (de) | Xenogene oligo- oder/und polyribonukleotide als mittel zur behandlung von malignen tumoren | |
| EP1206267A1 (de) | Arzneimittel enthaltend xenogene oligo- oder/und polyribonukleotide | |
| HK1030887B (en) | Treatment of bladder cancer by mycobacterium phlei cell wall | |
| DE69919386T2 (de) | Zusammensetzung zur behandlung von entzündungen | |
| MXPA00008142A (en) | Composition and method for the treatment of bladder cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8381 | Inventor (new situation) |
Inventor name: PHILLIPS, C., NIGEL, POINTE-CLAIRE, CA Inventor name: FLLION, C., MARIO, LAVAL, CA |
|
| 8381 | Inventor (new situation) |
Inventor name: PHILLIPS, C., NIGEL, POINTE-CLAIRE, CA Inventor name: FILION, C., MARIO, LAVAL, CA |
|
| 8364 | No opposition during term of opposition | ||
| R082 | Change of representative |
Ref document number: 1003525 Country of ref document: EP Representative=s name: VIERING, JENTSCHURA & PARTNER, DE |